Why the study?
Does prophylactic levosimendan reduce the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device in patients with reduced left ventricular ejection fraction undergoing cardiac surgery with cardiopulmonary bypass?
Does prophylactic levosimendan reduce the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device in patients with reduced left ventricular ejection fraction undergoing cardiac surgery with cardiopulmonary bypass?
Answers are grounded in this paper and cite their sources.
Prophylactic levosimendan does not improve short-term clinical outcomes in patients with reduced LVEF undergoing cardiac surgery with cardiopulmonary bypass.
Prophylactic levosimendan did not result in a rate of the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction, or use of a mechanical cardiac assist device that was lower than the rate with placebo among patients with a reduced left ventricular ejection fraction who were undergoing cardiac surgery with the use of cardiopulmonary bypass. (Funded by Tenax Therapeutics; LEVO-CTS ClinicalTrials.gov number, NCT02025621 .).
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: